MedTrace Logo

Adjuvant Therapy With Apatinib for HCC Patients With PVTT Who Underwent Radical Resection

NCT03261791 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-08-25

No results posted yet for this study

Summary

In this phase 2 study, we aim to evaluate the effects and safety of adjuvant apatinib therapy for the patients who underwent R0 resection for hepatocellular carcinoma with portal vein tumor thrombus.

Conditions

  • Carcinoma, Hepatocellular

Interventions

DRUG

Apatinib

Apatinib mesylate tablets 500 mg po qd.

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    lead OTHER

Principal Investigators

  • Hui-CHuan Sun, MD&PhD · Fudan University

  • Jia Fan, MD&PhD · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-20
Primary Completion
2020-01-20
Completion
2020-04-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03261791 on ClinicalTrials.gov